Market Place
Sourcing Support
Pfizer`s LORBRENA Showed 5+ Year PFS In ALK+ Lung Cancer CROWN Study
01 Jun 2024 //
BUSINESSWIRE
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023
17 Oct 2023 //
PR NEWSWIRE
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib
16 Oct 2023 //
PR NEWSWIRE
PF Prism`s Generic Xalkori, Crizotinib Receives Approval in the U.S.
07 Sep 2023 //
FDA
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer
16 May 2023 //
PRESS RELEASE
Pharma companies boost drug prices to start year, but hikes lag inflation
04 Jan 2023 //
BIOPHARMADIVE
IDEAYA Receives Fast Track Designation for Darovasertib with Crizotinib
05 Dec 2022 //
PRNEWSWIRE
Pfizer launches rebate program for rare disease patients
10 Aug 2022 //
ENDPOINTS NEWS
AnHeart Receives FDA Breakthrough Therapy Designation
03 Aug 2022 //
BUSINESSWIRE
Amber Specialty Added to Pfizer’s Limited Distribution Network
03 Aug 2022 //
BUSINESSWIRE
Pfizer gains its fourth FDA approval for an ALK-positive tumors
16 Jul 2022 //
FIERCEPHARMA
FDA clears Xalkori for inflammatory myofibroblastic tumours
15 Jul 2022 //
PHARMAPHORUM
IDEAYA, Pfizer Expand Trial Collaboration for Darovasertib and Crizotinib
14 Mar 2022 //
PRNEWSWIRE
Takeda offers value-based pricing for Alunbrig
09 Nov 2021 //
FIERCEPHARMA
IDEAYA Announces Dose Expansion in Ph1/2 Study of Darovasertib and Crizotinib
10 May 2021 //
PRNEWSWIRE
Pfizer`s Xalkori follow-up, which smoked the older drug in 1st-line patients
04 Mar 2021 //
ENDPTS
FDA approves crizotinib for children certain anaplastic large cell lymphomas
19 Jan 2021 //
EUROPEANPHARMACEUTICALREVIEW
FDA clears Pfizer`s Xalkori for ALK-positive ALCL in children, young adults
15 Jan 2021 //
BUSINESSWIRE
Pfizer’s XALKORI®Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma
14 Jan 2021 //
BUSINESSWIRE
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196
05 Jan 2021 //
PRESS RELEASE
FDA sets January decision date for Xalkori in ALK-positive lymphoma
26 Sep 2020 //
PMLIVE
IDEAYA &Pfizer Expand Collaboration to Evaluate Combination of IDE196+Crizotinib
24 Sep 2020 //
PRNEWSWIRE
FDA Accepts Supplemental NDA for Pfizer’s XALKORI® (crizotinib)
23 Sep 2020 //
BUSINESSWIRE
FDA Accepts Supplemental NDA for Pfizer’s XALKORI® (crizotinib)
22 Sep 2020 //
BIOSPACE
CROWN TRIAL SUPPORTS LORLATINIB AS A FUTURE FIRST-LINE STANDARD TREATMENT
21 Sep 2020 //
ESMO
Pfizer`s Lorbrena blows Xalkori for front-line ALK-positive lung cancer use
21 Sep 2020 //
FIERCE PHARMA
Pfizer`s Lorbrena makes play for earlier lung cancer use
05 Aug 2020 //
FIERCE PHARMA
Roche`s Alecensa stays on top of Xalkori at 5-year mark
13 May 2020 //
FIERCE PHARMA
NICE final guidance backs Pfizer`s Lorviqua
13 May 2020 //
PHARMA TIMES
Takeda Announces U.S. FDA Grants Priority Review for sNDA for ALUNBRIG®
24 Feb 2020 //
BUSINESSWIRE
Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce of Xalkori
23 Nov 2019 //
FIERCE PHARMA
Merck KGaA touts FDA `breakthrough` status
12 Sep 2019 //
ENDPOINTS NEWS
Pairing targeted drugs could overcome breast, lung cancer treatment resistance
11 Jul 2019 //
PHARMATIMES
Roche fields first approval for Rozlytrek
19 Jun 2019 //
ENDPTS
Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal
18 Jun 2019 //
FIERCE PHARMA
MET inhibitors from Incyte/Novartis and Germany`s Merck face off
05 Jun 2019 //
ENDPTS
Turning Point shares slide on 82% NSCLC ORR
04 Jun 2019 //
FIERCE BIOTECH
Pfizer scores conditional EU approval in ALK-positive lung cancer with Lorviqua
08 May 2019 //
PHARMAFILE
FDA plans to create a new office to leverage cutting-edge science
05 Jan 2019 //
STAT NEWS
U.S. FDA Approves LORBRENA® (lorlatinib) for met NSCLC
02 Nov 2018 //
BUSINESSWIRE
Pfizer racks up 3rd cancer drug OK, but can it replace regular price hikes?
02 Nov 2018 //
ENDPTS
Takeda to Present Results on Efficacy of ALUNBRIG® (brigatinib) vs Crizotinib
19 Oct 2018 //
BUSINESSWIRE
AmoyDx Lung Cancer CDx Approved in South Korea
12 Oct 2018 //
GENOMEWEB
Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts
11 Oct 2018 //
FIERCE PHARMA
Preliminary NICE ‘no’ for Takeda’s Alunbrig
03 Oct 2018 //
PHARMA TIMES
Takeda`s Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use
26 Sep 2018 //
FIERCE PHARMA
Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial
26 Sep 2018 //
BUSINESSWIRE
Bristol-Myers to sell Opdivo in China at half-price: report
22 Aug 2018 //
FIERCE PHARMA
China Unveils Cancer Drugs for Medical Insurance Access Negotiation
21 Aug 2018 //
BIOCENTURY
Roche`s Alecensa latest beneficiary of faster China drug approvals
20 Aug 2018 //
REUTERS
China Drug Admin grants Approval of Roche’s Alecensa for ALK+ lung cancer
20 Aug 2018 //
PRESS RELEASE
Pfizer`s Xalkori makes it onto Cancer Drugs Fund
31 May 2018 //
PHARMA TIMES
Takeda shareholders fear dilution, debt from Shire deal
30 May 2018 //
FIERCE PHARMA
Pfizer`s Xalkori picks up FDA `breakthrough` tags in lung cancer, lymphoma
30 May 2018 //
FIERCE PHARMA
Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation
29 May 2018 //
BUSINESSWIRE
Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at ASCO
19 May 2018 //
BUSINESSWIRE
Enforcement Report - Week of May 16, 2018
16 May 2018 //
FDA
Anvisa approves new indication of medicine for lung cancer
03 Apr 2018 //
PR NEWSWIRE
U.S. to cover advanced genomic testing for Medicare cancer patients
16 Mar 2018 //
REUTERS
